CA3045110A1 - Derives de tyrosine et compositions les comprenant - Google Patents

Derives de tyrosine et compositions les comprenant Download PDF

Info

Publication number
CA3045110A1
CA3045110A1 CA3045110A CA3045110A CA3045110A1 CA 3045110 A1 CA3045110 A1 CA 3045110A1 CA 3045110 A CA3045110 A CA 3045110A CA 3045110 A CA3045110 A CA 3045110A CA 3045110 A1 CA3045110 A1 CA 3045110A1
Authority
CA
Canada
Prior art keywords
cancer
tyrosine
methyl
composition
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3045110A
Other languages
English (en)
Inventor
Steven Hoffman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tyme Inc
Original Assignee
Tyme Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/365,120 external-priority patent/US20170080093A1/en
Application filed by Tyme Inc filed Critical Tyme Inc
Publication of CA3045110A1 publication Critical patent/CA3045110A1/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention concerne des compositions et des kits comprenant un inhibiteur de la tyrosine hydroxylase et un agent anticancéreux qui est chimiquement lié à, ou physiquement associé à, l'inhibiteur de la tyrosine hydroxylase. L'invention concerne également des procédés de réduction de la prolifération cellulaire chez un sujet comprenant l'administration à un sujet qui en a besoin d'une composition comprenant un inhibiteur de la tyrosine hydroxylase et un agent anticancéreux qui est lié chimiquement à, ou physiquement associé à, l'inhibiteur de la tyrosine hydroxylase.
CA3045110A 2016-11-30 2017-11-30 Derives de tyrosine et compositions les comprenant Pending CA3045110A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/365,120 US20170080093A1 (en) 2013-10-22 2016-11-30 Tyrosine Derivatives And Compositions Comprising Them
US15/365,120 2016-11-30
PCT/US2017/063865 WO2018102506A1 (fr) 2016-11-30 2017-11-30 Dérivés de tyrosine et compositions les comprenant

Publications (1)

Publication Number Publication Date
CA3045110A1 true CA3045110A1 (fr) 2018-06-07

Family

ID=60703174

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3045110A Pending CA3045110A1 (fr) 2016-11-30 2017-11-30 Derives de tyrosine et compositions les comprenant

Country Status (12)

Country Link
EP (1) EP3548086A1 (fr)
JP (2) JP2019536783A (fr)
KR (1) KR20190089191A (fr)
CN (1) CN110062633A (fr)
AU (1) AU2017368135A1 (fr)
BR (1) BR112019011033A2 (fr)
CA (1) CA3045110A1 (fr)
EA (1) EA201991305A1 (fr)
IL (1) IL266840A (fr)
MX (1) MX2019006326A (fr)
PH (1) PH12019501186A1 (fr)
WO (1) WO2018102506A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111743887A (zh) * 2019-03-26 2020-10-09 深圳先进技术研究院 α-甲基酪氨酸或其衍生物的用途
WO2020232227A1 (fr) 2019-05-14 2020-11-19 Tyme, Inc. Compositions et méthodes de traitement du cancer
CN115379851A (zh) * 2019-11-07 2022-11-22 因斯瑞拜奥有限公司 使用生长因子抗体与非酪氨酸靶向激酶抑制剂的组合的方法和组合物
IL294803A (en) * 2020-01-17 2022-09-01 Tyme Inc Tyrosine derivatives for modulating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI323662B (en) * 2002-11-15 2010-04-21 Telik Inc Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
WO2005072061A2 (fr) * 2004-02-02 2005-08-11 Biosight Ltd. Remedes conjugues de therapie et diagnostic du cancer
BRPI0621580B8 (pt) * 2006-04-19 2021-05-25 Univ Texas composto derivado de n4 e kit compreendendo o referido composto e um agente redutor
HRP20160625T1 (hr) * 2007-09-10 2016-08-12 Boston Biomedical, Inc. Novi inhibitori stat3 signalnog puta i inhibitori matičnih stanica raka
PH12014501639B1 (en) * 2012-01-17 2023-02-22 Tyme Inc Pharmaceutical compositions and methods
US9585841B2 (en) * 2013-10-22 2017-03-07 Tyme, Inc. Tyrosine derivatives and compositions comprising them

Also Published As

Publication number Publication date
KR20190089191A (ko) 2019-07-30
BR112019011033A2 (pt) 2019-10-15
PH12019501186A1 (en) 2020-02-10
AU2017368135A1 (en) 2019-06-13
JP2022153587A (ja) 2022-10-12
EA201991305A1 (ru) 2019-10-31
MX2019006326A (es) 2019-07-12
WO2018102506A1 (fr) 2018-06-07
JP2019536783A (ja) 2019-12-19
IL266840A (en) 2019-07-31
EP3548086A1 (fr) 2019-10-09
CN110062633A (zh) 2019-07-26

Similar Documents

Publication Publication Date Title
US20220313642A1 (en) Tyrosine derivatives and compositions comprising them
US8481498B1 (en) Pharmaceutical compositions and methods
US10307465B2 (en) Pharmaceutical compositions and methods
CA2862689C (fr) .alpha.-methyl-dl-tyrosine, compositions, trousses, combinaisons et utilisation associee destines au traitement du cancer ou a la reduction de la proliferation cellulaire
JP2022153587A (ja) チロシン誘導体及びそれらを含む組成物
US10507198B2 (en) Pharmaceutical compositions and methods
US20200345753A1 (en) Pharmaceutical compositions for the treatment of cancer
CA3040922A1 (fr) Compositions pharmaceutiques et procedes pour le traitement du cancer
US20210106549A1 (en) Pharmaceutical compositions and methods
US11103559B2 (en) Pharmaceutical compositions and methods
US20210386832A1 (en) Pharmaceutical Compositions And Methods

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20221130

N11 Application terminated

Free format text: ST27 STATUS EVENT CODE: T-6-6-N10-N11-N106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION NOT REINSTATED BY DEADLINE

Effective date: 20250530

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251229

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260112